Trodelvy was the last mTNBC drug to be approved. It received accelerated approval and marketing based on phase 2 trial data and then received full approval on the interim data from it's phase 3 trial. On the metrics we do know leronlimab beats Trodelvy and doesn't have the nasty side effects.

Cytodyn is unlikely to receive accelerated approval based on phase 2 data because of the trial size. However after approval of any other indication in 2022 Cytodyn will have the funds to expand the patient population in phase 3 and is likely to get accelerated approval and marketing at interim on phase 3 and full approval at the end of the trial.